Your browser doesn't support javascript.
Genomic surveillance of the Lambda SARS-CoV-2 variant in a global phylogenetic context.
Mestanza, Orson; Lizarraga, Wendy; Padilla-Rojas, Carlos; Jimenez-Vasquez, Víctor; Hurtado, Verónica; Molina, Iris S; Barcena, Luis; Acedo, Steve; Nuñez, Alicia; Gordillo, Sara; Sevilla, Nieves; Medrano, Princesa; Bailon, Henri; Cáceres, Omar; Galarza, Marco; Rojas-Serrano, Nancy; Vargas-Herrera, Natalia; Lope-Pari, Priscila; Huayra, Joseph; Araujo-Castillo, Roger V; Solari, Lely.
  • Mestanza O; Laboratorio de Referencia Nacional de Biotecnología y Biología Molecular, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Lizarraga W; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Padilla-Rojas C; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Jimenez-Vasquez V; Laboratorio de Referencia Nacional de Virus Respiratorios, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Hurtado V; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Molina IS; Laboratorio de Referencia Nacional de Virus Respiratorios, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Barcena L; Laboratorio de Referencia Nacional de Biotecnología y Biología Molecular, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Acedo S; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Nuñez A; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Gordillo S; Laboratorio de Referencia Nacional de Virus Respiratorios, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Sevilla N; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Medrano P; Laboratorio de Referencia Nacional de Virus Respiratorios, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Bailon H; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Cáceres O; Laboratorio de Referencia Nacional de Virus Respiratorios, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Galarza M; Laboratorio de Referencia Nacional de Biotecnología y Biología Molecular, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Rojas-Serrano N; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Vargas-Herrera N; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Lope-Pari P; Laboratorio de Referencia Nacional de Virus Respiratorios, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Huayra J; Laboratorio de Referencia Nacional de Biotecnología y Biología Molecular, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Araujo-Castillo RV; National Genomic Surveillance Program for SARS-CoV-2, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
  • Solari L; Laboratorio de Referencia Nacional de Biotecnología y Biología Molecular, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
J Med Virol ; 94(10): 4689-4695, 2022 10.
Article in English | MEDLINE | ID: covidwho-1866549
ABSTRACT
The massive sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and global genomic surveillance strategies allowed the detection of many variants of concern and interest. The variant of interest Lambda (C.37), which originated in South America, has been the most prevalent in Peru and Chile, but its dispersion in other continents still remains unknown. The current study aims to determine the phylogenetic relationship among C.37 isolates worldwide, focusing on spike mutations to understand the spread of Lambda in pandemics. A total of 7441 sequences identified as C.37 were downloaded from the GISAID database; local analysis was carried out to identify spike mutations and phylogenetic analysis was carried out to determine the rate of spread of the virus. Our results showed some spike mutations of Lambda that allowed us to detect small local outbreaks in different countries that occurred in the past and identify several clades that have not yet been designated. Although the lineage C.37 is not epidemiologically relevant in Europe or North America, the endemic behavior of this variant in Peru had a major impact on the second SARS-CoV-2 wave.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: South America / Chile Language: English Journal: J Med Virol Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: South America / Chile Language: English Journal: J Med Virol Year: 2022 Document Type: Article